Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the best biotech stocks with high potential. H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Beam Therapeutics Inc. (NASDAQ:BEAM) on September 15, retaining the price target of $80.
The analyst supported the optimistic rating with the company’s strong momentum in its in vivo and ex vivo base editing programs.
Similarly, in a report released on September 10, Kostas Biliouris from BMO Capital also maintained a Buy rating on Beam Therapeutics Inc. and set a price target of $40.00.
Biliouris supported the optimistic rating with the company’s technological advancements and strong position in the AATD market, adding that management’s confidence in the competitive positioning of BEAM-302 is a crucial reason for the bullish stance.
Beam Therapeutics Inc. is a biotechnology company that develops precision genetic medicines through base editing, a technology that allows efficient and predictable single-base changes at targeted genomic sequences. The company’s lead programs focus on sickle cell disease and alpha-1 antitrypsin deficiency.
Beam Therapeutics Inc. is advancing programs in other genetic diseases as well, along with oncology and immunology.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
